Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal irinotecan + platinum + tislelizumab + anlotinib
- Development stage
- Unknown
- Lead developer
- China Medical University
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This combination chemo-immunotherapy regimen is being investigated for the treatment of extensive-stage small cell lung cancer (ES-SCLC). The regimen consists of an induction phase utilizing liposomal irinotecan (a nanoparticle-encapsulated topoisomerase I inhibitor), a platinum agent (cisplatin or carboplatin), the anti-PD-1 monoclonal antibody tislelizumab, and the multi-targeted tyrosine kinase inhibitor anlotinib. This is followed by a maintenance phase of tislelizumab and anlotinib. Liposomal irinotecan is designed to provide sustained drug release and enhanced intratumoral accumulation compared to conventional irinotecan. Tislelizumab restores anti-tumor immune responses by blocking the PD-1/PD-L1 pathway, while anlotinib inhibits tumor angiogenesis and proliferation by targeting VEGFR, FGFR, PDGFR, and c-Kit. The regimen is currently being evaluated in Phase II clinical trials sponsored by China Medical University.
- Other names
- Liposomal Irinotecan, Platinum, Tislelizumab, and AnlotinibLiposome Irinotecan + Platinum + Tislelizumab + Anlotinib
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on liposomal irinotecan + platinum + tislelizumab + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal irinotecan + platinum + tislelizumab + anlotinib.